LEXEO THERAPEUTICS INC (LXEO) Fundamental Analysis & Valuation

NASDAQ:LXEO • US52886X1072

Current stock price

5.72 USD
+0.05 (+0.88%)
At close:
5.72 USD
0 (0%)
After Hours:

This LXEO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. LXEO Profitability Analysis

1.1 Basic Checks

  • LXEO had negative earnings in the past year.
  • LXEO had a negative operating cash flow in the past year.
  • LXEO had negative earnings in each of the past 5 years.
  • In the past 5 years LXEO always reported negative operating cash flow.
LXEO Yearly Net Income VS EBIT VS OCF VS FCFLXEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • LXEO's Return On Assets of -72.97% is on the low side compared to the rest of the industry. LXEO is outperformed by 64.41% of its industry peers.
  • The Return On Equity of LXEO (-86.87%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -72.97%
ROE -86.87%
ROIC N/A
ROA(3y)-58.41%
ROA(5y)-45.95%
ROE(3y)-74.86%
ROE(5y)-56.75%
ROIC(3y)N/A
ROIC(5y)N/A
LXEO Yearly ROA, ROE, ROICLXEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

  • LXEO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LXEO Yearly Profit, Operating, Gross MarginsLXEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. LXEO Health Analysis

2.1 Basic Checks

  • There is no outstanding debt for LXEO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LXEO Yearly Shares OutstandingLXEO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
LXEO Yearly Total Debt VS Total AssetsLXEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

  • LXEO has an Altman-Z score of 5.71. This indicates that LXEO is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 5.71, LXEO is in the better half of the industry, outperforming 74.66% of the companies in the same industry.
  • LXEO has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.00, LXEO is in line with its industry, outperforming 49.90% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.71
ROIC/WACCN/A
WACCN/A
LXEO Yearly LT Debt VS Equity VS FCFLXEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 7.40 indicates that LXEO has no problem at all paying its short term obligations.
  • LXEO's Current ratio of 7.40 is fine compared to the rest of the industry. LXEO outperforms 69.25% of its industry peers.
  • LXEO has a Quick Ratio of 7.40. This indicates that LXEO is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of LXEO (7.40) is better than 69.83% of its industry peers.
Industry RankSector Rank
Current Ratio 7.4
Quick Ratio 7.4
LXEO Yearly Current Assets VS Current LiabilitesLXEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. LXEO Growth Analysis

3.1 Past

  • LXEO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.90%, which is quite impressive.
EPS 1Y (TTM)28.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • LXEO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.42% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y29.21%
EPS Next 2Y17.36%
EPS Next 3Y12.89%
EPS Next 5Y23.42%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LXEO Yearly Revenue VS EstimatesLXEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
LXEO Yearly EPS VS EstimatesLXEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4 6

More info and screens

Find the best growth stocksShow best growing peers

0

4. LXEO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for LXEO. In the last year negative earnings were reported.
  • Also next year LXEO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LXEO Price Earnings VS Forward Price EarningsLXEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LXEO Per share dataLXEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as LXEO's earnings are expected to grow with 12.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.36%
EPS Next 3Y12.89%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LXEO Dividend Analysis

5.1 Amount

  • LXEO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LXEO Fundamentals: All Metrics, Ratios and Statistics

LEXEO THERAPEUTICS INC

NASDAQ:LXEO (4/2/2026, 8:00:01 PM)

After market: 5.72 0 (0%)

5.72

+0.05 (+0.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-30
Earnings (Next)N/A
Inst Owners105.59%
Inst Owner Change48.96%
Ins Owners0.85%
Ins Owner Change7.2%
Market Cap417.50M
Revenue(TTM)N/A
Net Income(TTM)-104.97M
Analysts88.24
Price Target20.03 (250.17%)
Short Float %17.98%
Short Ratio13.79
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)25.64%
Min EPS beat(2)13.49%
Max EPS beat(2)37.78%
EPS beat(4)3
Avg EPS beat(4)8.16%
Min EPS beat(4)-23.91%
Max EPS beat(4)37.78%
EPS beat(8)5
Avg EPS beat(8)0.05%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0.82%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.46
P/tB 3.46
EV/EBITDA N/A
EPS(TTM)-2.19
EYN/A
EPS(NY)-1.55
Fwd EYN/A
FCF(TTM)-1.47
FCFYN/A
OCF(TTM)-1.46
OCFYN/A
SpS0
BVpS1.66
TBVpS1.66
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -72.97%
ROE -86.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.41%
ROA(5y)-45.95%
ROE(3y)-74.86%
ROE(5y)-56.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.17%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.4
Quick Ratio 7.4
Altman-Z 5.71
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)146.13%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.38%
EPS Next Y29.21%
EPS Next 2Y17.36%
EPS Next 3Y12.89%
EPS Next 5Y23.42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-21.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2.66%
EBIT Next 3Y-9.58%
EBIT Next 5YN/A
FCF growth 1Y-36.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-36.4%
OCF growth 3YN/A
OCF growth 5YN/A

LEXEO THERAPEUTICS INC / LXEO Fundamental Analysis FAQ

What is the fundamental rating for LXEO stock?

ChartMill assigns a fundamental rating of 2 / 10 to LXEO.


Can you provide the valuation status for LEXEO THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to LEXEO THERAPEUTICS INC (LXEO). This can be considered as Overvalued.


How profitable is LEXEO THERAPEUTICS INC (LXEO) stock?

LEXEO THERAPEUTICS INC (LXEO) has a profitability rating of 0 / 10.